Storia in 4 fonti

Biogen pushing tau drug forward despite Alzheimer’s study failure

One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo3 mesi fa

Biogen pushing tau drug forward despite Alzheimer’s study failure

One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.

originale

Timeline cronologica

giovedì 14 maggio 2026·biopharmadive.com
Biogen pushing tau drug forward despite Alzheimer’s study failure
One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase…
giovedì 14 maggio 2026·statnews.com
Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study
Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.

Biogen pushing tau drug forward despite Alzheimer’s study failure

Confronto fonti

Biogen pushing tau drug forward despite Alzheimer’s study failure

Timeline cronologica

Biogen pushing tau drug forward despite Alzheimer’s study failure

Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Updated: Biogen won’t be ‘impulsive’ with anti-tau Alzheimer’s drug

Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study

Updated: Biogen won’t be ‘impulsive’ with anti-tau Alzheimer’s drug

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data